Han Mingyu, Wan Feng, Xiao Bin, Du Junrong, Peng Cheng, Peng Fu
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China.
State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China.
Chin Med J (Engl). 2025 Apr 20;138(8):905-915. doi: 10.1097/CM9.0000000000003341. Epub 2024 Nov 8.
Lung cancer is one of the most lethal tumors in the world with a 5-year overall survival rate of less than 20%, mainly including lung adenocarcinoma (LUAD). Tumor microenvironment (TME) has become a new research focus in the treatment of lung cancer. The TME is heterogeneous in composition and consists of cellular components, growth factors, proteases, and extracellular matrix. The various cellular components exert a different role in apoptosis, metastasis, or proliferation of lung cancer cells through different pathways, thus contributing to the treatment of adenocarcinoma and potentially facilitating novel therapeutic methods. This review summarizes the research progress on different cellular components with cell-cell interactions in the TME of LUAD, along with their corresponding drug candidates, suggesting that targeting cellular components in the TME of LUAD holds great promise for future theraputic development.
肺癌是世界上最致命的肿瘤之一,其5年总生存率低于20%,主要包括肺腺癌(LUAD)。肿瘤微环境(TME)已成为肺癌治疗的新研究热点。TME的组成具有异质性,由细胞成分、生长因子、蛋白酶和细胞外基质组成。各种细胞成分通过不同途径在肺癌细胞的凋亡、转移或增殖中发挥不同作用,从而有助于腺癌的治疗并可能促进新的治疗方法。本综述总结了LUAD的TME中不同细胞成分及其细胞间相互作用的研究进展,以及相应的候选药物,表明针对LUAD的TME中的细胞成分在未来治疗发展中具有巨大潜力。
Adv Exp Med Biol. 2016
Cancer Immunol Immunother. 2024-3-2
Am J Cancer Res. 2023-6-15
J Exp Clin Cancer Res. 2023-6-12